Pluristem Therapeutics, Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company’s first planned product, PLX-I, targets a $3 billion annual market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT). Pluristem also believes its PLacental eXpanded (PLX) cells will be helpful for a variety of other indication, including as a help to patients afflicted with Peripheral Artery Disease (PAD) with critical limb ischemia (CLI).

Geron is focused on developing and commercializing therapeutic and diagnostic products for cancer based on our telomerase technology, and cell-based therapeutics using our human embryonic stem cell technology.

Develops proprietary patient-specific cell therapeutics for stem cell tissue repair, and the treatment of cancer and infectious disease.